AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Summary

A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AK135 for the treatment of chemotherapy-induced peripheral neuropathy in patients with malignant tumor

Timeline

Start

2025-02-28

Primary completion

2026-03-31

Completion

2027-12-31

Drugs

Indications